Sustained glucagon‐like peptide‐1 receptor agonist treatment improves glycemic control and reduces all‐cause mortality compared to dipeptidyl peptidase‐4 inhibitors: A real‐world target trial emulation in type 2 diabetes

Ähnliche Einträge

• Glucagon‐like‐peptide‐1 receptor agonists versus dipeptidyl peptidase‐4 inhibitors and cardiovascular outcomes in diabetes in relation to achieved glycemic control. A Danish nationwide study
  von: Bochra Zareini, et al.
  Veröffentlicht: (2024)
• Cheap Subsampling bootstrap confidence intervals for fast and robust inference
  von: Ohlendorff, Johan Sebastian, et al.
  Veröffentlicht: (2025)
• A cohort description and comparison of four European national diabetes registries for the REDDIE project
  von: Jonah J. C. Thomas, et al.
  Veröffentlicht: (2025)
• Poor socioeconomic outcomes: Completion of the final examination after lower secondary education mitigates risks associated with gestational age
  von: Rikke Wiingreen, et al.
  Veröffentlicht: (2024)
• Frequency of hypoglycaemia with basal insulin treatments in adults with type 1 diabetes treated with basal‐bolus insulin regimens in treat‐to‐target trials: A narrative review
  von: David Russell‐Jones, et al.
  Veröffentlicht: (2024)